A Phase I Study of MK-4827 for Treatment of Solid Tumors (MK-4827-005)
NCT01226901
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
3
Enrollment
INDUSTRY
Sponsor class
Conditions
Neoplasms
Solid Tumors
Interventions
DRUG:
MK-4827
Sponsor
Merck Sharp & Dohme LLC